User:Hsbwjuz/Thomsen–Friedenreich antigen

This is the sandbox page where you will draft your initial Wikipedia contribution.

If you're starting a new article, you can develop it here until it's ready to go live.

If you're working on improvements to an existing article, copy only one section at a time of the article to this sandbox to work on, and be sure to use an edit summary linking to the article you copied from. Do not copy over the entire article. You can find additional instructions here.

Remember to save your work regularly using the "Publish page" button. (It just means 'save'; it will still be in the sandbox.) You can add bold formatting to your additions to differentiate them from existing content.

Bibliography sandbox

Article Draft

Lead

Thomsen–Friedenreich antigen (Galβ1-3GalNAcα1-Ser/Thr) is a disaccharide that serves as a core 1 structure in O-linked glycosylation.^[1] First described by Thomsen as a red blood cell's antigen, later research have determined it to be an oncofetal antigen.^[2] it is present in the body as a part of membrane transport proteins where it is normally masked from the immune system.^[3] It is commonly demasked in cancer cells, with it being expressed in up to 90% of carcinomas, making it a potential target for immunotherapy.^[2]

References

^ Yu, Lu-Gang (2007). "The oncofetal Thomsen–Friedenreich carbohydrate antigen in cancer progression". Glycoconjugate Journal. 24 (8): 411–20. doi:10.1007/s10719-007-9034-3. PMID 17457671.
^ ^a ^b Kurtenkov, Oleg (2020-03-24). "Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential". BioMed Research International. 2020: 1–12. doi:10.1155/2020/9747040. ISSN 2314-6133.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ Karsten, U.; Goletz, S. (2015-07-XX). "What controls the expression of the core-1 (Thomsen—Friedenreich) glycotope on tumor cells?". Biochemistry (Moscow). 80 (7): 801–807. doi:10.1134/S0006297915070019. ISSN 0006-2979. {{cite journal}}: Check date values in: |date= (help)

[1] Yu, Lu-Gang (2007). "The oncofetal Thomsen–Friedenreich carbohydrate antigen in cancer progression". Glycoconjugate Journal. 24 (8): 411–20. doi:10.1007/s10719-007-9034-3. PMID 17457671.

[:0-2] Kurtenkov, Oleg (2020-03-24). "Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential". BioMed Research International. 2020: 1–12. doi:10.1155/2020/9747040. ISSN 2314-6133.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[3] Karsten, U.; Goletz, S. (2015-07-XX). "What controls the expression of the core-1 (Thomsen—Friedenreich) glycotope on tumor cells?". Biochemistry (Moscow). 80 (7): 801–807. doi:10.1134/S0006297915070019. ISSN 0006-2979. {{cite journal}}: Check date values in: |date= (help)

[1]

[2]

[3]